{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:50:50Z","timestamp":1793397050119,"version":"4.5.0"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["ATVB"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:p>FXI (factor XI) and FXII (factor XII) have emerged as targets for new anticoagulants that have the potential to be both more efficacious and safer than the currently available direct oral anticoagulants for the prevention and treatment of venous thromboembolism. In this review, we discuss the role of FXI and FXII in the pathogenesis of venous thromboembolism, explain why FXI is a better target, and explain why FXI inhibitors have potential advantages over currently available anticoagulants. Finally, we describe the FXI inhibitors under development and discuss their potential to address unmet needs in venous thromboembolism management.<\/jats:p>","DOI":"10.1161\/atvbaha.123.318781","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T05:00:30Z","timestamp":1693458030000},"page":"1755-1763","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":34,"title":["New Therapeutic Targets for the Prevention and Treatment of Venous Thromboembolism With a Focus on Factor XI Inhibitors"],"prefix":"10.1161","volume":"43","author":[{"given":"Noel C.","family":"Chan","sequence":"first","affiliation":[{"name":"Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada (N.C.C., J.I.W.)."},{"name":"Department of Medicine (N.C.C., J.I.W.), McMaster University, Hamilton, Ontario, Canada."},{"name":"Population Health Research Institute, Hamilton, Ontario, Canada (N.C.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-7550","authenticated-orcid":true,"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[{"name":"Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada (N.C.C., J.I.W.)."},{"name":"Department of Medicine (N.C.C., J.I.W.), McMaster University, Hamilton, Ontario, Canada."},{"name":"Department of Biochemistry and Biomedical Sciences (J.I.W.), McMaster University, Hamilton, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2015.83"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.114.304488"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.306925"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32439-9"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026723"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14548"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-571232"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005819"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001830"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003442"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000919"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615066"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61753-4"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302097"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.30091"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2018.12.022"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","unstructured":"Vanassche T Rosovsky RP Moustafa F B\u00fcller HR Segers A Patel I Shi M Miyoshi N Mani V Fayad Z et al. Inhibition of thrombin-activatable fibrinolysis inhibitor via DS-1040 to accelerate clot lysis in patients with acute pulmonary embolism: a randomized phase 1b study [published online May 11 2023]. J Thromb Haemost. doi: 10.1016\/j.jtha.2023.04.037. https:\/\/www.jthjournal.org\/article\/S1538-7836(23)00398-7\/fulltext","DOI":"10.1016\/j.jtha.2023.04.037"},{"key":"e_1_3_3_19_2","unstructured":"Clinicaltrials.gov. Novel \u03b12-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) trial. ClinicalTrials.gov identifier: NCT05408546. Updated July 11 2023. Accessed August 8 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05408546"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009428"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15689"},{"key":"e_1_3_3_22_2","unstructured":"Clinicaltrials.gov. Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement (COURSE). ClinicalTrials.gov identifier: NCT03812328. Updated January 6 2021. Accessed August 8 2023. https:\/\/clinicaltrials.gov\/study\/NCT03812328?tab=results"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.056355"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.10.008"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.27.7.517"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-012110-142305"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI60229"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04544.x"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201719"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1005743107"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20112322"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-199182"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615947"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.06.010"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH16-09-0691"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-734988"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-569111"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0270865"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-463646"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-540872"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-364141"},{"key":"e_1_3_3_42_2","first-page":"1087","article-title":"Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis.","volume":"134","author":"Drake TA","year":"1989","unstructured":"Drake, TA, Morrissey, JH, Edgington, TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol. 1989;134:1087\u20131097.","journal-title":"Am J Pathol"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.3109\/10409238.2015.1050550"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2014.1.66"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199107183250303"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","unstructured":"Bolton-Maggs PH. Factor XI deficiency--resolving the enigma? Hematology Am Soc Hematol Educ Program. 2009;97\u2013105. doi: 10.1182\/asheducation-2009.1.97. https:\/\/ashpublications.org\/hematology\/article\/2009\/1\/97\/19841\/Factor-XI-deficiency-resolving-the-enigma","DOI":"10.1182\/asheducation-2009.1.97"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04844.x"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15037"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1735971"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.119.026545"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04311.x"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15820"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2009.11.028"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq349"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019644"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12663"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2016.0623"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad123"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00613"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15588"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15230"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405760"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.20687"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2113194"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105872"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1055\/a-2043-0346"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.903029"},{"key":"e_1_3_3_68_2","unstructured":"Clinicaltrials.gov. A study comparing abelacimab to apixaban in the treatment of cancer-associated VTE (ASTER). ClinicalTrials.gov identifier: NCT05171049. Updated August 14 2023. Accessed August 31 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05171049"},{"key":"e_1_3_3_69_2","unstructured":"Clinicaltrials.gov. A study comparing abelacimab to dalteparin in the treatment of gastrointestinal\/genitourinary cancer and associated VTE (MAGNOLIA). ClinicalTrials.gov identifier: NCT05171075. Updated August 14 2023. Accessed August 31 2023. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05171075"}],"container-title":["Arteriosclerosis, Thrombosis, and Vascular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/ATVBAHA.123.318781","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T14:01:32Z","timestamp":1747836092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/ATVBAHA.123.318781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":68,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1161\/ATVBAHA.123.318781"],"URL":"https:\/\/doi.org\/10.1161\/atvbaha.123.318781","relation":{},"ISSN":["1079-5642","1524-4636"],"issn-type":[{"value":"1079-5642","type":"print"},{"value":"1524-4636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"2023-06-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}